Related Experiment Videos
[Immunosuppressive therapy in pure red cell aplasia]
Deutsche Medizinische Wochenschrift (1946)
|January 17, 1975
Summary
Cyclophosphamide treatment induced a sustained remission in a patient with acquired erythroblastic aplasia of adults, a rare bone marrow disorder. Bone marrow biopsy confirmed active erythropoiesis, reflecting the positive clinical outcome.
Area of Science:
- Hematology
- Oncology
- Internal Medicine
Background:
- Acquired erythroblastic aplasia of adults is a rare hematologic disorder.
- It is characterized by the absence of red blood cell precursors in the bone marrow.
- Long-term management often requires transfusions and immunosuppressive therapy.
Purpose of the Study:
- To report a case of acquired erythroblastic aplasia of adults.
- To evaluate the efficacy of cyclophosphamide in inducing remission.
- To correlate bone marrow histology with clinical response.
Main Methods:
- A 34-year-old female patient with a 7-year history of the disease was treated.
- Initial treatment involved glucocorticoids, followed by regular transfusions.
- Cyclophosphamide was administered, and bone marrow biopsies were performed.
Main Results:
- Cyclophosphamide treatment resulted in a remission lasting over twelve months.
- Bone marrow histology post-treatment showed active erythropoiesis.
- This histological finding correlated with the clinical improvement.
Conclusions:
- Cyclophosphamide can be an effective treatment for acquired erythroblastic aplasia of adults.
- Sustained remission is achievable with appropriate therapy.
- Monitoring bone marrow histology aids in assessing treatment response.